Literature DB >> 33642851

Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia.

Heba K Nabih1.   

Abstract

BACKGROUND: The global coronavirus disease 2019 (COVID-19) was announced as pandemic by the World Health Organization (WHO). With the increased number of infected and dead victims daily all over the world, it becomes necessary to stop or overcome its rapid spread.Main bodyAlthough the production of vaccine or even specified effective anti-virus may take about six months to a year, intravenous immunoglobulin (IVIg) may be clinically used as a safe treatment to save and improve the quality of life of patients with a variety of immunodeficiency diseases such as lymphocytopenia, which is a common clinical feature in COVID-19.
CONCLUSION: Through the current review, it was concluded that this passive immunization may promote the immunity to better fight against the virus, so the survival of the patients could be kept longer. The efficacy of immunotherapy with IVIg would be greater if the immune IgG antibodies were collected from convalescent plasma therapy.
© The Author(s) 2021.

Entities:  

Keywords:  COVID-19; Convalescent plasma therapy; Immunoglobulins; Immunotherapy; Lymphocytopenia; Passive immunization

Year:  2021        PMID: 33642851      PMCID: PMC7897881          DOI: 10.1186/s42269-021-00502-4

Source DB:  PubMed          Journal:  Bull Natl Res Cent        ISSN: 1110-0591


  33 in total

Review 1.  IGIV: contents, properties, and methods of industrial production--evolving closer to a more physiologic product.

Authors:  Turf D Martin
Journal:  Int Immunopharmacol       Date:  2005-12-13       Impact factor: 4.932

Review 2.  Use of intravenous immunoglobulin G (IVIG).

Authors:  R John Looney; Jennifer Huggins
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

Review 3.  History of immunoglobulin replacement.

Authors:  Martha M Eibl
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

4.  The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma.

Authors:  J L ONCLEY; M MELIN
Journal:  J Am Chem Soc       Date:  1949-02       Impact factor: 15.419

Review 5.  Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance.

Authors:  M Radosevich; T Burnouf
Journal:  Vox Sang       Date:  2009-07-29       Impact factor: 2.144

6.  Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.

Authors:  J Andersson; U Skansén-Saphir; E Sparrelid; U Andersson
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

Review 7.  Intravenous immune globulin in autoimmune and inflammatory diseases.

Authors:  Erwin W Gelfand
Journal:  N Engl J Med       Date:  2012-11-22       Impact factor: 91.245

8.  Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.

Authors:  Y Uemura; Y H Yang; C M Heldebrant; K Takechi; K Yokoyama
Journal:  Vox Sang       Date:  1994       Impact factor: 2.144

9.  Modulation of complement-mediated immune damage by intravenous immune globulin.

Authors:  M Basta
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

10.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.

Authors:  Chenguang Shen; Zhaoqin Wang; Fang Zhao; Yang Yang; Jinxiu Li; Jing Yuan; Fuxiang Wang; Delin Li; Minghui Yang; Li Xing; Jinli Wei; Haixia Xiao; Yan Yang; Jiuxin Qu; Ling Qing; Li Chen; Zhixiang Xu; Ling Peng; Yanjie Li; Haixia Zheng; Feng Chen; Kun Huang; Yujing Jiang; Dongjing Liu; Zheng Zhang; Yingxia Liu; Lei Liu
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

View more
  2 in total

1.  COVID-19-specific transcriptomic signature detectable in blood across multiple cohorts.

Authors:  Tommi Välikangas; Sini Junttila; Kalle T Rytkönen; Anu Kukkonen-Macchi; Tomi Suomi; Laura L Elo
Journal:  Front Genet       Date:  2022-08-05       Impact factor: 4.772

Review 2.  Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease.

Authors:  Maria Giovanna Danieli; Mario Andrea Piga; Alberto Paladini; Eleonora Longhi; Cristina Mezzanotte; Gianluca Moroncini; Yehuda Shoenfeld
Journal:  Scand J Immunol       Date:  2021-09-16       Impact factor: 3.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.